Cytos Biotechnology - Board &Management

Board &

Management

Home
Contact
Directions
Glossary
Site Map
Disclaimer

Cytos

Press Releases

Cytos

Facts & Figures

Cytos Biotechnology AG
Wagistrasse 25
Postfach
8952 Schlieren
Switzerland
T +41 44 733 47 47
F +41 44 733 47 40
e-mail contact

Cytos Biotechnology's management team has a proven track record of turning technology into products, managing risk, and meeting milestones. It is backed by an outstanding Board of Directors with in-depth experience in the pharmaceutical industry. Please click on the link of interest below to view the biographies of the members of the Executive Board and the Board of Directors. The Executive Board The Board of Directors
The Executive Board

Wolfgang A. Renner, PhD in biotechnology, has been heading the Company since its incorporation and has been Delegate of the Board of Directors and Chief Executive Officer of Cytos since July 1998. He obtained his PhD in 1995 from the Swiss Federal Institute of Technology (ETH), Zurich. It was his thesis that provided the basis for the foundation of Cytos Biotechnology GmbH in 1995. His achievements were honored with the “ETH Medal” 1991, the first prize of the “Swiss Economic Award” 1999, the “Entrepreneur of the Year 2000 Award”, the “CASH-GDI Award” 2003 (category: knowledge maker), the third prize of the “European BioTechnica Award of Excellence in Biotech Business” 2004, and the “Swiss Equity Award” 2006. He is a member of the Committee of Science and Technology of the Swiss Federation of Commerce and Industry (Economiesuisse) and of the Foundation Council of the Swiss National Science Foundation.

Martin F. Bachmann, PhD in molecular biology, has been Executive Vice President and Chief Scientific Officer of Cytos since October 1999. He received his PhD in 1995 at the Institute for Experimental Immunology, Zurich, in the laboratories of Nobel Laureate Prof. Zinkernagel and Prof. Hengartner. In 2005, he received a teaching position (Venia Legendi) for Immunology from the University of Zurich. He is author of more than 190 articles in internationally renowned scientific journals. His achievements were honored with two “ETH Medals” (1991 and 1995), the Pfizer Prize for Immunology (1998), and the Swiss Technology Award (2004).

Mark Dyer, PhD in molecular biology, has been Executive Vice President Business Development and Strategy of Cytos since July 2001. He was awarded a PhD in 1988 from the University of Cambridge, UK, where he studied with Nobel Laureate Sir John Walker at the MRC Laboratory of Molecular Biology. He has 20 years of pharmaceutical and biotechnology industry experience gained in Europe and the U.S. In 1993, he joined Sandoz AG (later: Novartis Pharma AG, Basel) as a member of global research management, where he was responsible for external research collaborations and from where he joined Cytos.

Frank Hennecke, PhD in molecular biology, has been Executive Vice President Product Development of Cytos since April 2001. He obtained his PhD in molecular biology from the University of Gottingen, Germany, in 1996. After a postdoctoral fellowship in the group of Prof. Pluckthun at the University of Zurich, he joined Cytos in 1998. Under his guidance, the development of a number of manufacturing processes for pharmaceutical proteins could be completed successfully and full GMP compliant manufacturing processes for Immunodrugs™ have been implemented at Cytos.

Philipp Müller, MD, has been Executive Vice President Clinical Development of Cytos since March 2003. He received his MD from the University of Basel and also holds a Clinical Pharmacologist SKP degree of the Swiss Society for Clinical Pharmacology. He joined Cytos from Novartis Pharma AG, where he has been active in different functions in human pharmacology and clinical research, in the last seven years as Deputy of Global Head Clinical Pharmacology. He brings more than 20 years of experience to Cytos.

Hans Stocker, PhD in biology, has been Executive Vice President Regulatory Affairs since December 2004. He received his PhD from the University of Zurich. He brings more than 25 years of experience in clinical and regulatory affairs to Cytos. From 2002–2003, he was head of the Swiss Agency for Therapeutic Products (Swissmedic) and managed the five preceding years its predecessor organization, the Intercantonal Office for the Control of Medicines (IKS). Before this, he held senior positions with Johnson & Johnson’s Pharmaceutical Research Institute and with Cilag AG.

Harry Welten, MBA (Hons.), joined Cytos Biotechnology in June 2010 as Chief Financial Officer. Harry has more than 20 years of international senior executive experience, nine of which in biotech. Prior to joining Cytos he was CFO at Nitec Pharma AG in Reinach which he successfully merged with the US based Horizon Pharma Inc. in order to go public at the US stock market later in 2010. From 2001 to 2009, Harry was CFO at Arpida AG where he raised more than CHF 250 million in private equity and public monies including the Initial Public Offering at the SIX Swiss Exchange in 2005. In 2009, he successfully restructured Arpida AG following a major regulatory set back, spun-off its lead asset and subsequently acquired Evolva AG in order for them to become a listed company. Prior to joining Arpida, he was a Director at UBS Warburg in New York following various senior positions within the UBS Group. Before joining UBS, he was with ABB and DaimlerChrysler. Harry is a member of the Board of Directors of Synosia Therapeutics, a company based in San Francisco and Basel which develops and intends to commercialise innovative products for unmet medical needs in psychiatry and neurology. Harry holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York.

top

The Board of Directors

Thomas Hecht, MD, in April 2010 he has been elected as the Chairman of the Board of Directors, he has been a member of the Board of Directors since April 2003. He was vice president marketing (hematology, oncology, new products) for Amgen (Europe) AG from 1999 until 2002. Before this, he held different marketing and medical affairs positions at Amgen (Europe) AG, and at Amgen GmbH, Germany. He was co-head of the program for bone marrow transplantation, University of Freiburg i. Br., Germany, and worked as a physician at the University of Freiburg i. Br., Germany, for several years. Today, he provides services to the pharmaceutical industry in medical/marketing development and licensing strategies through HHC, a biopharmaceutical consulting company founded in 2002. He serves as chairman of the boards of Delenex Therapeutics AG, Affimed Therapeutics AG, Telormedix AG, Lipideon Biotechnology AG and SuppreMol GmbH. In 2009, he stepped down from the board of Esbatech AG.

Thorlef Spickschen, Dr. rer. pol., has been a member of the Board of Directors since April 2003. From 1994 to 2001 he was chairman and CEO of BASF Pharma/Knoll AG. Before this, he held executive positions at Boehringer Mannheim GmbH and at Eli Lilly. He is chairman of the board of BIOTEST AG and member of the board of Clovis Oncology, Inc. He also serves as a member of the supervisory board of the OrthopaedicClinic of the University of Heidelberg. He is also chairman of the Investors Advisory Board of Heidelberg Innovation and of the German Kidney Foundation Support Society.

Wolfgang A. Renner, PhD in biotechnology, is one of the founders and an important shareholder of Cytos. He has been heading the Company since its incorporation and has been a member of the Board of Directors since July 1998 and serves as CEO and Delegate. For a detailed description see “Management – Executive Board”.

Jean-Yves le Cotonnec, MD, MSc (Mathematics and Statistics) and advanced degree in electronic engineering, has been a member of the Board of Directors since April 2003. He is founder and president of Triskel Integrated Services S.A. founded in 1995, a company providing integrated strategic services to the pharmaceutical and device industry. Before this, he held several management positions in product development at Serono, the “Institut des Technologies pour la Sante”, and Zyma S.A. (now Novartis Healthcare). He is a member of the Scientific Advisory Board of Eclosion S.A.

Sir Mark H. Richmond, PhD, ScD in molecular biology, has been a member of the Board of Directors since September 1999. Previously, he was head of worldwide research with the former Glaxo Group from 1993 to 1996 and chairman of the British Science and Engineering Research Council. Since his retirement in 1996 he acted as board member in different biotech and pharmaceutical companies. At present he serves on the board of Ark Therapeutics Ltd.

Jakob Schlapbach, Lic. rer. pol. and MBA (INSEAD), has been Executive Vice President and Chief Financial Officer of Cytos since June 2000 and in April 2010 he was elected to the Board of Directors. He received his degree in Economics from the University of Berne in 1979, followed by an MBA at INSEAD in Fontainebleau, France, in 1984. He has more than 25 years of banking and industrial financing experience. Before joining Cytos, he was CFO of two publicly quoted international companies, at the latest from 1994–2000 at Ascom group. He was elected CFO of the year 2002 by the renowned Swiss newspaper “Finanz und Wirtschaft”. He is a member of the board of directors of Lipideon Biotechnology AG.

Othmar T. Vock, holder of a Swiss Federal diploma from the “Handelsschule des Technikums Winterthur”, served as CFO and member of the Executive Committee of Givaudan SA, from 2000 to 2004, when he retired. He has been a member of the Board of Directors of Cytos Biotechnology since April 2006. Before becoming CFO of Givaudan, he was employed in several finance positions at the Roche Group, where he held amongst other positions the post of internal auditor and was the Roche delegate and CFO for the fragrance/flavours business division. He also served in different positions at the Ciba Geigy Group in Brazil and Switzerland. Since his retirement he acts as a board member in different boards. At present he is a member of the boards of Swisscom AG and Ivoclar Vivadent AG. On both boards mentioned, Othmar T. Vock is chairman of the audit committee.
top